| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
179,400,000 |
| Market
Cap: |
313.95(M) |
| Last
Volume: |
1,560,200 |
Avg
Vol: |
2,306,261 |
| 52
Week Range: |
$0.449 - $1.83 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Nektar Therapeutics is a research-based biopharmaceutical company. Co.'s research and development pipeline of investigational drugs includes potential therapies for cancer and autoimmune disease. Co.'s proprietary programs include: Immuno-oncology, which involves in developing medicines that target biological pathways which stimulate and sustain the body's immune response in order to fight cancer; and Pain, NKTR-181, a mu-opioid analgesic drug candidate patients with chronic low back pain. Co.'s NKTR-358 is an investigational drug designed to correct the underlying immune system imbalance in the body which occurs in patients with autoimmune disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
92,653 |
92,653 |
204,995 |
510,803 |
| Total Sell Value |
$124,554 |
$124,554 |
$194,453 |
$1,231,647 |
| Total People Sold |
4 |
4 |
7 |
10 |
| Total Sell Transactions |
4 |
4 |
13 |
34 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Greer R Scott |
Director |
– • – |
2018-09-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,750 |
135,083 |
|
- |
|
| Lingnau Lutz |
Director |
– • – |
2018-09-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,750 |
23,200 |
|
- |
|
| Chess Robert |
Director |
– • – |
2018-09-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,750 |
274,473 |
|
- |
|
| Eastham Karin |
Director |
– • – |
2018-09-27 |
4 |
A |
$0.00 |
$0 |
D/D |
8,500 |
8,500 |
|
- |
|
| Ajer Jeffrey Robert |
Director |
– • – |
2018-09-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,750 |
20,500 |
|
- |
|
| Whitfield Roy A |
Director |
– • – |
2018-09-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,750 |
181,750 |
|
- |
|
| Kuebler Christopher A |
Director |
– • – |
2018-09-27 |
4 |
A |
$0.00 |
$0 |
D/D |
4,750 |
45,250 |
|
- |
|
| Lingnau Lutz |
Director |
– • – |
2018-09-20 |
4 |
AS |
$56.98 |
$512,820 |
D/D |
(9,000) |
18,450 |
|
- |
|
| Ajer Jeffrey Robert |
Director |
– • – |
2018-09-20 |
4 |
AS |
$56.76 |
$383,130 |
D/D |
(6,750) |
15,750 |
|
- |
|
| Chess Robert |
Director |
– • – |
2018-09-19 |
4 |
AS |
$56.81 |
$255,645 |
D/D |
(4,500) |
269,723 |
|
- |
|
| Greer R Scott |
Director |
– • – |
2018-09-04 |
4 |
AS |
$67.39 |
$673,900 |
D/D |
(10,000) |
130,333 |
|
- |
|
| Greer R Scott |
Director |
– • – |
2018-09-04 |
4 |
OE |
$5.14 |
$51,400 |
D/D |
10,000 |
140,333 |
|
- |
|
| Winger Dennis L |
Director |
– • – |
2018-08-21 |
4 |
S |
$60.30 |
$904,500 |
D/D |
(15,000) |
42,750 |
|
- |
|
| Winger Dennis L |
Director |
– • – |
2018-08-21 |
4 |
OE |
$14.26 |
$213,900 |
D/D |
15,000 |
57,750 |
|
- |
|
| Winger Dennis L |
Director |
– • – |
2018-08-17 |
4 |
S |
$59.62 |
$894,300 |
D/D |
(15,000) |
42,750 |
|
- |
|
| Winger Dennis L |
Director |
– • – |
2018-08-17 |
4 |
OE |
$14.26 |
$213,900 |
D/D |
15,000 |
57,750 |
|
- |
|
| Hora Maninder |
SVP Pharma Dev & Mfg Ops |
• – – |
2018-08-16 |
4 |
D |
$58.40 |
$347,246 |
D/D |
(5,946) |
85,723 |
|
- |
|
| Doberstein Stephen K |
SVP & Chief Scientific Officer |
• – – |
2018-08-16 |
4 |
D |
$58.40 |
$391,338 |
D/D |
(6,701) |
83,258 |
|
- |
|
| Nicholson John |
SVP & Chief Operating Officer |
• – – |
2018-08-16 |
4 |
D |
$58.40 |
$475,201 |
D/D |
(8,137) |
180,459 |
|
- |
|
| Thomsen Jillian B. |
SVP & Chief Accounting Officer |
• – – |
2018-08-16 |
4 |
D |
$58.40 |
$285,167 |
D/D |
(4,883) |
71,265 |
|
- |
|
| Robin Howard W |
President & CEO |
• • – |
2018-08-16 |
4 |
D |
$58.40 |
$1,190,718 |
D/D |
(20,389) |
264,467 |
|
- |
|
| Labrucherie Gil M |
SVP & Chief Financial Officer |
• – – |
2018-08-16 |
4 |
D |
$58.40 |
$479,289 |
D/D |
(8,207) |
113,059 |
|
- |
|
| Hora Maninder |
SVP Pharma Dev & Mfg Ops |
• – – |
2018-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
91,669 |
|
- |
|
| Doberstein Stephen K |
SVP & Chief Scientific Officer |
• – – |
2018-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
26,000 |
89,959 |
|
- |
|
| Nicholson John |
SVP & Chief Operating Officer |
• – – |
2018-08-15 |
4 |
A |
$0.00 |
$0 |
D/D |
26,000 |
188,596 |
|
- |
|
913 Records found
|
|
Page 13 of 37 |
|
|
